MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-26-2026
Aileron Therapeutics Operating Expenses 2011-2026 | ALRN
Annual Operating Expenses Aileron Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 50.6 M | 65.1 M | 16.3 M | 27.6 M | 26.6 M | 20.5 M | 30 M | 31.9 M | 23 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 65.1 M | 16.3 M | 32.4 M |
Quarterly Operating Expenses Aileron Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.49 M | 6.87 M | 5.61 M | - | 6.07 M | 9.04 M | 7.2 M | - | 1.98 M | 1.99 M | 5.01 M | - | 6.48 M | 8.04 M | 8.42 M | - | 6.79 M | 6.01 M | 6.99 M | 4.19 M | 5.03 M | 4.4 M | 6.88 M | 7.35 M | 7.92 M | 7.38 M | 7.31 M | 6.98 M | 7.5 M | 9.66 M | 7.76 M | 7.04 M | 6.43 M | 4.95 M | 4.59 M | 4.45 M | 4.23 M | 5.55 M | 3.94 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 9.66 M | 1.98 M | 6.16 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aligos Therapeutics
ALGS
|
90.2 M | $ 8.57 | -0.81 % | $ 84.7 M |  USA |
 |
Allakos
ALLK
|
196 M | - | - | $ 28.6 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
16.7 M | $ 3.73 | 1.78 % | $ 8.97 B |  Australia |
 |
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | USA |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
BioNTech SE
BNTX
|
512 M | $ 99.22 | 2.61 % | $ 27.2 B | Germany |
 |
Burford Capital Limited
BUR
|
106 M | $ 4.68 | 4.23 % | $ 760 M |  Britain |
 |
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
Cabaletta Bio
CABA
|
172 M | $ 3.26 | 1.87 % | $ 328 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B |  France |
 |
Brainstorm Cell Therapeutics
BCLI
|
31.7 M | - | -2.5 % | $ 5.88 M | USA |
 |
Applied Therapeutics
APLT
|
74.5 M | - | - | $ 8.42 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
854 M | - | - | $ 546 M | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
216 M | $ 21.41 | 0.21 % | $ 1 B | USA |
 |
Checkpoint Therapeutics
CKPT
|
56.2 M | - | - | $ 169 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | USA |
 |
Clearside Biomedical
CLSD
|
33.1 M | - | - | $ 25.3 M | USA |
 |
Aeterna Zentaris
AEZS
|
13.3 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
173 M | $ 1.53 | 4.08 % | $ 393 M | USA |
 |
Evogene Ltd.
EVGN
|
13.8 M | $ 0.82 | 0.51 % | $ 27.9 M |  Israel |
|
Forte Biosciences
FBRX
|
70.7 M | $ 32.45 | 6.03 % | $ 420 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 3.03 | 3.7 % | $ 4.99 M | Israel |
 |
Aquestive Therapeutics
AQST
|
85.5 M | $ 4.15 | -0.95 % | $ 444 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
137 M | $ 25.2 | 4.48 % | $ 3.21 B | USA |
 |
Chimerix
CMRX
|
93.4 M | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
110 M | - | - | $ 401 M | USA |
 |
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | USA |
 |
Celldex Therapeutics
CLDX
|
58.1 M | $ 33.28 | 2.12 % | $ 2.21 B | USA |
 |
Galectin Therapeutics
GALT
|
20.1 M | $ 2.45 | 4.26 % | $ 157 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.5 | 2.04 % | $ 399 M | Britain |
 |
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Cidara Therapeutics
CDTX
|
177 M | - | - | $ 1.41 B | USA |
 |
AVROBIO
AVRO
|
71.7 M | - | 1083.1 % | $ 745 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
16 M | $ 2.61 | 7.19 % | $ 1.16 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | Israel |
 |
AstraZeneca PLC
AZN
|
17.6 B | - | - | $ 96.9 B | Britain |
 |
Grifols, S.A.
GRFS
|
1.64 B | $ 8.56 | 2.39 % | $ 6.83 B |  Spain |